Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on...
Pharmaceutical Veteran to Help Propel Manufacturing Scale-Up as Clinical-Stage Biotech Prepares to Enter Phase 2 Clinical TrialsNEW HAVEN, Conn., April...
Enable Cloud Platform trained on high plex spatial imaging datasets across 20,000 samples run on the PhenoCycler® SystemCommercial launch at...
Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin...
Dr. Redkar to discuss importance of HGF/cMET pathway, which can play critical role in origin of several cancersFOSTER CITY, Calif.,...
Eight Abstracts Demonstrate Progress of Prelude’s Differentiated PipelineWILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD),...
MINNEAPOLIS, April 11, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy...
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated with INB-100 will be presented;...
The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk...
Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential of TAILWIND® platform to create...
Dr. De La Rosa adds over 20 years of big pharma and biotech infectious disease clinical trial experience to Curevo...
In IND-enabling studies, HSB-1216 remained tightly bound within the Quatramer™ until reaching its tumor target, consistent with earlier pre-clinical studies...
MINNEAPOLIS, April 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
FREMONT, CA, April 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company...
BERKELEY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today...
Shannon R. Morris, M.D., Ph.D., promoted to Chief Medical Officer Chandra D. Lovejoy promoted to Chief Regulatory Affairs Officer SAN...
Phase 1b study builds on highly consistent preclinical and Phase 1a dataFort Lee, NJ, April 10, 2023 (GLOBE NEWSWIRE) --...
Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer Webcast scheduled for Tuesday, April 18th...